- Details
- Description
-
Packaging Size1bottle/Box
-
Strength125mg(10mL)
-
CompositonCadonilimab
-
TreatmentRelapsed or metastatic cervical cancer
-
FormInjection
-
Brand开坦尼
-
Quantity Unit125mg(10mL)/Bottle/Box
-
ManufacturerAkeso, Inc.,China
Cadonilimab is a bispecific antibody that targets the PD-1 and CTLA-4 receptors on tumor cells to treat various solid cancers. In June 2022, cadonilimab was approved in China for use in patients with relapsed or metastatic cervical cancer.
- Cadonilimab sold under the brand name 开坦尼® in china.